|
|
| In this picture from left to right: Jan Hed, Gunilla Ekström, Owe Gårlin and Lennart Lundberg. |
|
|
Senior management |
 | Owe Gårlin
CEO BSc, Business Administration
Born 1949
AnaMar is led by CEO Owe Gårlin. Mr. Gårlin has over 30 years of pharmaceutical industry experience, including as CEO for Zeneca in Sweden and CEO for Sanofi-Synthelabo in the Nordic region prior to joining AnaMar in 2004. |
|
Gunilla Ekström
VP R&D PhD, Ass Prof.
Born 1958 The research and development activity is led by Gunilla Ekström, PhD, and Associate Professor at the Department of Cell and Organism Biology at Lund University, who joined the Company in 2003. Dr. Ekström has almost twenty years of pharma R&D experience with a focus on inflammation and arthritis, and leads a team of ten in R&D, six of whom are PhD's. |  |
|
 | Lennart Lundberg
VP Intellectual Property PhD. Prof.
Born 1953
Overseeing the AnaMar's intellectual property is Lennart Lundberg. Prof. Lundberg has over 20 years experience with AstraZeneca including responsibility for biotech patents within cardiovascular and gastrointestinal units, and also as project leader, alliance manager and principal scientist with over 70 papers published in the fields of biochemistry, biotechnology and gene technology. He is an inventor of several patents/patent applications. |
|
 Jan Hed
Scientific advisor
MD, PhD, Ass Prof.
Born 1947
Jan Hed serves as scientific advisor to the Company. Dr. Hed is an Associate professor of Clinical Immunology at the Karolinska Institute in Stockholm, Sweden, with more than 100 published scientific papers. He is also a co-founder of the Company and the former CEO of AnaMar and Absorber AB as well as Deputy VP R&D with Pharmacia & Upjohn Diagnostics. |
|
|
|
|
|
|
